HomeCompareSCRPF vs JNJ

SCRPF vs JNJ: Dividend Comparison 2026

SCRPF yields 3.81% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.9K in total portfolio value· pulled ahead in Year 6
10 years
SCRPF
SCRPF
● Live price
3.81%
Share price
$5.30
Annual div
$0.20
5Y div CAGR
-46.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$0.70
Full SCRPF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SCRPF vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCRPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCRPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCRPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCRPF
Annual income on $10K today (after 15% tax)
$323.67/yr
After 10yr DRIP, annual income (after tax)
$0.60/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCRPF + JNJ for your $10,000?

SCRPF: 50%JNJ: 50%
100% JNJ50/50100% SCRPF
Portfolio after 10yr
$25.3K
Annual income
$2,345.05/yr
Blended yield
9.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SCRPF
No analyst data
Altman Z
1.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCRPF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCRPFJNJ
Forward yield3.81%2.13%
Annual dividend / share$0.20$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-46.9%28%
Portfolio after 10y$20.4K$30.3K
Annual income after 10y$0.70$4,689.40
Total dividends collected$436.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SCRPF vs JNJ ($10,000, DRIP)

YearSCRPF PortfolioSCRPF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,902$202.20$10,592$272.30+$310.00SCRPF
2$11,775$109.40$11,289$357.73+$486.00SCRPF
3$12,658$58.63$12,123$472.89+$535.00SCRPF
4$13,575$31.28$13,141$629.86+$434.00SCRPF
5$14,542$16.65$14,408$846.81+$134.00SCRPF
6← crossover$15,569$8.85$16,021$1,151.60$452.00JNJ
7$16,663$4.70$18,122$1,588.22$1.5KJNJ
8$17,832$2.50$20,930$2,228.20$3.1KJNJ
9$19,082$1.33$24,792$3,191.91$5.7KJNJ
10$20,418$0.70$30,274$4,689.40$9.9KJNJ

SCRPF vs JNJ: Complete Analysis 2026

SCRPFStock

Sembcorp Industries Ltd, an investment holding company, engages in the renewables, integrated urban solutions, conventional energy, and other businesses in Singapore, rest of southeast Asia, the Middle East, China, India, the United Kingdom, and internationally. The Renewables segment provides electricity from solar and wind resources and energy storage solutions, as well as system services that support integration of renewables into grid; and trades in energy attribute certificates. This segment also includes the development and provision of installation, operation, and maintenance of solar, wind, and energy storage assets. The Integrated Urban Solutions segment develops large-scale integrated urban and integrated townships, such as industrial parks, business, commercial and residential spaces, and production and reclamation of water and industrial wastewater treatment, as well as solid waste management and waste-to-resource solutions. This segment also comprises carbon capture, utilization, and storage projects. The Conventional Energy segment sells energy molecules, including natural gas, steam, and electricity from various fossil fuels, such as natural gas and coal. This segment also sells water products from its integrated assets. The company also engages in the terminalling and storage of petroleum products and chemicals; solid waste management, public cleaning, and recycling services; and construction and engineering related activities. In addition, it offers water products; and reclamation of water and industrial wastewater treatment services. The company was formerly known as Minaret Limited and changed its name to Sembcorp Industries Ltd in July 1998. Sembcorp Industries Ltd was incorporated in 1998 and is headquartered in Singapore.

Full SCRPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SCRPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCRPF vs SCHDSCRPF vs JEPISCRPF vs OSCRPF vs KOSCRPF vs MAINSCRPF vs ABBVSCRPF vs MRKSCRPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.